Literature DB >> 25225845

Developing an outcome measure for excessive saliva management in MND and an evaluation of saliva burden in Sheffield.

Alexander J McGeachan1, Esther V Hobson, Pamela J Shaw, Christopher J McDermott.   

Abstract

There are few studies providing evidence to guide the management of oropharyngeal secretion problems in motor neuron disease (MND). There is a lack of a suitable outcome measure for evaluating management strategies. We applied several potential outcome measures for assessing excessive secretions to patients with MND who attended the Sheffield Care and Research Centre for Motor Neurone Disease between 21 November 2012 and 15 May 2013. These measures were the CSS-MND, a symptom rating scale, and the Drool and Wipe quotient, which were designed to semi-objectively measure patients' drooling. Of the 143 patients seen in clinic during the study period, 58 had symptoms of excessive secretions, and of whom 50 agreed to participate in the study. Semi-objective measures failed to effectively identify patients complaining of secretion problems. The CSS-MND had a relatively low internal consistency (Cronbach's alpha 0.539; n = 50); however, analysis of the inter-item correlations suggested the appearance of low internal consistency was because the scale was measuring a variety of saliva related symptoms that did not necessarily influence each other. The scale correlated well with patient reported symptom impact (r = 0.673, n = 50). In conclusion, the CSS-MND would be a useful outcome measure in studies assessing the management of oropharyngeal secretion problems.

Entities:  

Keywords:  Outcome measures; amyotrophic lateral sclerosis; excessive saliva; motor neurone disease; secretion management; sialorrhoea

Mesh:

Year:  2014        PMID: 25225845     DOI: 10.3109/21678421.2014.951942

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  2 in total

1.  Radiotherapy treatment of sialorrhea in patients with amyotrophic lateral sclerosis requiring non-invasive ventilation.

Authors:  Maria del Mar Amador; Avi Assouline; Jésus Gonzalez-Bermejo; Pierre-François Pradat
Journal:  J Neurol       Date:  2015-07-15       Impact factor: 4.849

2.  SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxinA for sialorrhea.

Authors:  Wolfgang H Jost; Andrzej Friedman; Olaf Michel; Christian Oehlwein; Jaroslaw Slawek; Andrzej Bogucki; Stanislaw Ochudlo; Marta Banach; Fernando Pagan; Birgit Flatau-Baqué; János Csikós; Claire J Cairney; Andrew Blitzer
Journal:  Neurology       Date:  2019-03-27       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.